Gilles Divita

Company: Divincell

Job title: Chief Executive Officer

Seminars:

Unlocking Novel Peptide Delivery Platforms for More Selective RNA Delivery to Cells Outside the Liver 12:30 pm

Rational design of a peptide-based delivery system to overcome hepatic accumulations and to selectively target diseased tissues Unlocking new RNA-based therapeutic platform that leverages novel peptide technology capable of targeting and systemically delivering therapeutic RNA and gene editing machinery into the pathological cell to combat or prevent disease Demonstrating efficient mRNA delivery through systemic administration…Read more

day: Day 1

Expert Panel Discussion – De-Risking RNA Delivery Platforms Through Uncovering the Most Suitable Platforms for Your RNA Payloads to Ensure Effective Treatment 9:00 am

With an array of nonviral delivery carriers in development, how do you identify which is the most suitable method for your RNA therapeutic? How can the field leverage and learn from approved carriers, such as LNPs, to overcome 2024 IP complexities? When developing a novel delivery vehicle, how is the field de-risking their platforms to…Read more

day: Day 1

Unlocking Targeted Non-Viral Delivery Methods for RNA-Based Gene Editing Payloads to Minimize Toxic Effects for Improved Therapies 1:05 pm

Gene editing payloads contain both the editor and guide RNA, making them much more complex to package. Similarly, there is potential for toxic side effects of permanent off target editing, and such it is vital that drug developers employ cell specific delivery vehicles. Uncover the key principles for successful delivery of RNAbased gene editors to…Read more

day: Pre-Conference Day